Brian Rini, MD, on Expectations For a Trial Examining MK-1308A Plus Lenvatinib and Pembrolizumab With Other Combinations in ccRCC

Video

Brian I. Rini, MD, detailed the focus, goals, and key end points of a 3-arm, phase 3 trial comparing MK-1308A or belzutifan plus lenvatinib and pembrolizumab to the control of lenvatinib and pembrolizumab alone to treat patients with advanced clear cell renal cell carcinoma.

Brian I. Rini, MD, chief of clinical trials and professor of medicine at the Vanderbilt-Ingram Cancer Center, spoke with CancerNetwork® at the 2021 European Society for Medical Oncology (ESMO) Congress about his expectations for the results of the upcoming randomized, open-label, phase 3 trial (NCT04736706). The 3-arm study will compare MK-1308A or belzutifan (Welireg) added to lenvatinib (Lenvima) and pembrolizumab (Keytruda) versus the control arm of pembrolizumab plus lenvatinib to treat advanced clear cell renal cell carcinoma in the first-line setting.

Transcription:

The trial’s powered for overall survival and we’ll also look at progression-free survival, response rate, and other typical end points. If positive, it would presumably set a new standard of care and ideally care [for] more patients. We’re now at the point in kidney cancer where we’re curing around 15% to 20% of patients, but that’s obviously still the minority of patients. The hope is, as has been done in other malignancies, by building combination regimens, we can care more patients. That's absolutely the goal.

Reference

Rini BI, Plimack ER, Powles TB, et al. Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC). Ann Oncol. 2021;32(suppl 5):717TiP. doi:10.1016/annonc/annonc675

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content